Fluidigm Corporation announced today that the Group for Innovative Cancer Treatment Division of the National Cancer Center in Japan has expanded its clinical research in colorectal cancer using the Hyperion™ Imaging System to study regulatory T (Treg) cell proliferation in tumor tissue with the goal of discovering a novel target for immunotherapy.
Globally, colorectal cancer is the third most commonly occurring cancer in men and the second-most common in women. There were more than 1.8 million new cases worldwide in 2018.
Treg cells, a specialized subpopulation of T cells, are actively engaged in the maintenance of immunological self-tolerance and homeostasis. They are more frequently observed in tumor than in non-tumor tissue and are known to inhibit the development of effective anti-tumor immune responses. The research focused on colorectal cancer at the National Cancer Center’s Exploratory Oncology Research and Clinical Trial Center is under the direction of Hiroyoshi Nishikawa, MD, PhD, Chief, Division of Cancer Immunology.
“The Hyperion Imaging System provides a wealth of information from each tumor tissue sample by simultaneous analysis of up to 37 protein markers, providing a critical capability in our research into a potential therapy for colorectal cancer,” said Nishikawa. “This technology is an extremely valuable tool in our translational research and drug discovery efforts.”
Mass cytometry deeply profiles immune cell phenotypes and function and is the basis of hundreds of peer-reviewed publications documenting research on the frontiers of immunology, immuno-oncology and other realms of health and disease. The Hyperion Imaging System extends the use of mass cytometry technology and is revolutionizing high-multiplex tissue analysis by deeply characterizing the tumor microenvironment with an efficient one-scan workflow.
“The National Cancer Center has chosen the Hyperion Imaging System to deeply interrogate tissue samples for critical immuno-oncology work, and we are truly excited that our technology is supporting research toward a potential future therapy for a disease as globally prevalent as colorectal cancer,” said Chris Linthwaite, Fluidigm President and CEO.
“This is yet another example of multisystem placement in premier research centers that utilize our pioneering mass cytometry and Imaging Mass Cytometry™ systems to identify meaningful biomarkers and accelerate development of more impactful therapies,” Linthwaite said.